11.08.2016 • NewsBASFBatteriesElaine Burridge

BASF and Toda Kogyo Eye North American Battery Market

(c) Predrag Novakovic
(c) Predrag Novakovic

Germany’s BASF and Japan’s Toda Kogyo are in exclusive talks to extend an existing Japanese collaboration in cathode active materials (CAM) and precursors to North America. Last year, the companies established BASF Toda Battery Materials to provide CAM for lithium-ion batteries in Japan. A combination of their respective CAM businesses in North America would strengthen their alliance in the global market and create additional synergies, the companies said. BASF is to take a majority stake in the proposed venture.

The collaboration is planned to focus on manufacturing a broad range of CAM and precursors for lithium-ion batteries used in the automotive, consumer electronics and stationary storage markets. Tadashi Kubota, chairman of Toda Kogyo, noted that the automotive lithium-ion battery market is still in its infancy, with annual growth of above 30% expected in the coming years.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.